TRAJENTA®: Proven efficacy with the same dose regardless of renal function.

Patients with type 2 diabetes have a risk of declining renal function over time.1 Unlike most other DPP4 inhibitors, TRAJENTA® is not primarily excreted through the kidney. That means the same 5 mg once daily dose can be maintained throughout T2D management, even as kidney function declines.2 In clinical studies, TRAJENTA® has been proven an effective and safe method to achieve HbA1c reductions regardless of renal function.2-4

Adjusted mean HbA1c change vs placebo from baseline by degree of renal impairment (RI)**2-4

TRAJENTA® also has a favourable safety and tolerability profile.

**A small proportion of patients in these studies were receiving treatment combinations that fall outside of the licensed indications for TRAJENTA® (linagliptin).
†Prespecified subgroup analysis on pooled data from three pivotal Phase III, randomised placebo-controlled trials: treatment in monotherapy, add-on to metformin and add-on to metformin plus sulphonylurea. P values for between-group difference (versus placebo). Model includes continuous baseline HbA1c, baseline body mass index (category), washout period, treatment, study, age group, gender, time since diagnosis of diabetes, race, renal function (MDRD) and treatment × renal function (MDRD).
‡1-year, randomised, double-blind, placebo-controlled study: treatment added to existing background therapy. Data based on analysis using LOCF (last observation carried forward).